Skip to content

Veracyte VCYT Current ratio

Current ratio at other companies

Guardant Health logo
Guardant HealthGH
4.7×+0.6×
Natera, Inc. logo
Natera, Inc.NTRA
-0.9×
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
3.2×-2.8×
Revvity logo
RevvityRVTY
1.7×-1.9×
Labcorp Holdings logo
Labcorp HoldingsLH
1.7×-0.1×
Quest Diagnostics logo
Quest DiagnosticsDGX
1.2×-0.3×

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$4.28B+10.7%
Enterprise value$4.05B+7.4%
P/E48.6×-68.3×
P/S7.9×-0.4×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×

Where this comes from

Calculated from Veracyte’s reported figures.

Based on the most recent quarter.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veracyte's current ratio?
Veracyte (VCYT) reported current ratio of 9.3× in Q1 2026.
How has Veracyte's current ratio changed year-over-year?
Veracyte's current ratio increased by 82.5% year-over-year, from 5.1× to 9.3×.
What is the long-term trend for Veracyte's current ratio?
Over 5 years (2020 to 2025), Veracyte's current ratio has grown at a -18.3% compound annual growth rate (CAGR), from 22.4× to 8.1×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.